Site Search

The Patient Registry is an invaluable tool for researchers conducting observational studies about people with CF in the U.S. About 50,000 individuals have been followed in the Registry since its inception in 1986; many of them have been included for over 20 years.

The Success with Therapies Research Consortium helps the clinical study of interventions so people with cystic fibrosis can improve the consistency of their day-to-day management of their CF to optimize health outcomes and quality of life.

Learn how your child's safety is protected, what to expect during a trial, and how to involve your child in the decision-making process.

This competition is awarding one year of free lab and office space at Bakar Labs of University of California Berkeley to applicants with emerging technology in gene editing, gene delivery, and gene therapy/gene insertion that may be applied to CF. 

Once your clinical trial is over, you can follow its progress online or follow up with your care team to find out about results. Learn how to use the Clinical Trial Finder and Drug Development Pipeline to track your trial and stay informed about current research.

There are two main types of clinical studies in CF research. Both are important to move research forward and provide the best outcomes for people with CF.

Clinical trials are critical to developing new treatments for CF. So, how exactly does an experimental drug become an approved therapy?

Choosing to volunteer in a clinical trial is a personal decision. Through a process called informed consent, you can learn key facts about a study and get answers to your questions.

Cystic fibrosis occurs when the cystic fibrosis transmembrane conductance regulator (CFTR) protein is either not made correctly, or not made at all. By understanding how the protein is made, scientists have been able to develop treatments that target the protein and restore its function.

The Cystic Fibrosis Foundation is aggressively pursuing potential treatments for people with CF who have nonsense and rare mutations who will not benefit from drugs known as modulators, which correct the malfunctioning cystic fibrosis transmembrane conductance regulator (CFTR) protein.